Home Ingredients ResistAid® (Larch Arabinogalactan — Lonza)
Immune SupportGut Health

ResistAid® (Larch Arabinogalactan — Lonza)

Larix occidentalis
Evidence Level
Moderate
3 Clinical Trials
6 Documented Benefits
3/5 Evidence Score

ResistAid® is a standardized larch arabinogalactan ingredient developed by Lonza — sustainably-sourced from North American larch trees (Larix occidentalis) using a water-based extraction method. Distinguished by manufacturer-funded trials for immune support (a borderline reduction in common cold incidence and a selective rise in vaccine antibodies) plus a small trial showing shifts in gut microbiome composition. Used for: immune system support, gut health and prebiotic fiber.

Studied Dose 1.5 to 4.5 g/day in the immune and vaccine trials; 15 g/day in the microbiome trial.
Active Compound Arabinogalactan polysaccharide from Larix occidentalis larch; ResistAid® (Lonza).

Benefits

Common Cold Incidence (Borderline, Manufacturer-Funded)

In a 12-week trial of 199 healthy adults (4.5 g/day), the primary outcome of common cold incidence was not statistically significant (p = 0.055); a secondary count, the number of participants who caught a cold, was significantly lower on ResistAid (p = 0.038). Symptom severity at episode onset was actually higher on ResistAid. The trial was funded by the manufacturer, and no effect on influenza has been shown.

Supported by Trial 1

Vaccine Antibody Response (Selective, Surrogate)

In a 45-person pilot trial, ResistAid raised the IgG response to the pneumococcal vaccine for only 2 of 7 tested subtypes (18C and 23F); the other five were not significant. In a separate 75-person trial it raised tetanus IgG at 1.5 g/day but not at the higher 4.5 g/day dose, and had no effect on influenza antibodies. Both trials were manufacturer-funded and measured antibody titers, not fewer infections.

Supported by Trial 2

Gut Microbiome Modulation

In a 30-person crossover trial (15 g/day for 6 weeks) the fecal Firmicutes-to-Bacteroidetes ratio fell; Bifidobacterium only tended to increase and overall microbial diversity decreased. Lactobacillus was not shown to rise. The trial was manufacturer-funded and measured microbiome composition, not a clinical gut outcome.

Supported by Trial 3

NK Cell Activity (Proposed Mechanism, Not Shown in Trials)

Natural killer cell activation is a proposed mechanism from laboratory studies. In the human ResistAid vaccine trial the innate immune markers that were measured (white blood cell count, inflammatory cytokines, complement) did not change, so this remains a mechanism rather than a demonstrated human effect.

Supported by Trial 3, Trial 2

Sustainable Larch Source

Larch arabinogalactan extracted from sustainably-sourced North American larch chips using water-based extraction (no chemical solvents). Clean-label positioning.

Soluble Fiber / Prebiotic

ResistAid is a soluble fiber that bypasses upper GI digestion; fermented in the colon to produce short-chain fatty acids (in the human ResistAid trial the specific profile did not show a butyrate increase, and some minor fecal fatty acids fell).

Supported by Trial 3

Mechanism of action

1

Innate Immune Activation

Arabinogalactan binds to immune cell receptors; activates macrophages, dendritic cells, NK cells; enhances first-line immune response.

2

Adaptive Immune Support

ResistAid enhances B-cell antibody production — improved adaptive immune response to pathogens and vaccines.

3

Prebiotic Fermentation

Soluble fiber resists upper GI digestion; fermented in colon by beneficial bacteria; produces short-chain fatty acids supporting gut barrier and gut-immune axis.

4

Gut Microbiome Modulation

Selective stimulation of beneficial bacteria (Bifidobacterium, Lactobacillus); shifts microbiome composition toward healthier profile.

5

Larch Source Distinction

Larch arabinogalactan distinct from acacia gum arabic — different polysaccharide structure; specific immune evidence base.

Clinical trials

1
ResistAid for Cold Incidence
PubMed

Clinical trial of ResistAid 4.5 g/day for 12 weeks during cold season in healthy adults.

199 healthy adults during cold season.

Common cold incidence, the primary outcome, was not statistically significant (p = 0.055); the number of participants affected by a cold was significantly lower on ResistAid (p = 0.038), significant in the per-protocol set. Symptom severity at onset was higher on ResistAid. Manufacturer-funded.

2
ResistAid for Antibody Response
PubMed

Clinical trial of ResistAid effects on pneumococcal vaccine antibody response.

Adults receiving pneumococcal vaccine.

IgG response to the 23-valent pneumococcal vaccine was significantly greater on ResistAid for 2 of 7 subtypes (18C and 23F); the other five subtypes and salivary IgA were not significant. An antibody-titer surrogate, not fewer infections. Manufacturer-funded pilot (n=45).

3
ResistAid Gut Microbiome Study
PubMed

Randomized double-blind crossover trial (n=30) of ResistAid 15 g/day for 6 weeks on fecal microbiome composition and short-chain fatty acids in healthy adults.

Healthy adults.

At 15 g/day for 6 weeks the fecal Firmicutes-to-Bacteroidetes ratio fell and Bifidobacterium tended to rise, but overall microbial diversity decreased. No immune markers were measured. Manufacturer-funded crossover (n=30).

Side effects and drug interactions

Common Potential side effects

Generally extremely well-tolerated.
Mild GI distress (gas, bloating) at high doses — typical of soluble fiber adjustment.
Allergic reactions to larch rare.
Self-affirmed GRAS status.

Important Drug interactions

Generally minimal drug interactions.
Immunosuppressants — theoretical concern with immune-activating ingredients; consult.
Antibiotics — generally complementary; may help restore gut microbiome after antibiotic courses.
Pregnancy — generally considered safe; limited specific data.
Lactation — generally considered safe.
Children — safe at appropriate proportional doses; ResistAid studied in pediatric immune support.

Featured in these supplement guides

Immune Support→

More Immune Support Ingredients

Immune Support
Vitamin C
Vitamin C (L-ascorbic acid) is a water-soluble essential nutrient that humans cannot synth…
Immune Support
Zinc
Zinc, an essential trace mineral, is commonly supplemented in forms like zinc gluconate, a…
Immune Support
Zinc Acetate
Zinc acetate is zinc bound to acetic acid, a well-absorbed form that is among the best stu…
Immune Support
Bioferrin® (Lactoferrin — Glanbia)
Bioferrin® is a lactoferrin ingredient from Glanbia — distinguished by milk-derived lactof…

Explore Other Ingredients

Muscle & Recovery
L-Glutamine
L-glutamine is the most abundant amino acid in the body and the primary metabolic fuel for…
Metabolic Health
Chlorella
Chlorella is a single-celled freshwater green algae rich in chlorophyll, complete protein…
Muscle & Recovery
Bromelain
Bromelain is a group of protein-digesting enzymes extracted from pineapple stems, used in…

Frequently asked questions about ResistAid® (Larch Arabinogalactan — Lonza)

What is ResistAid?

ResistAid® is a standardized larch arabinogalactan ingredient developed by Lonza — sustainably-sourced from North American larch trees (Larix occidentalis) using a water-based extraction method.

What is ResistAid used for?

ResistAid is researched primarily for Immune Support and Gut Health. In a 12-week trial of 199 healthy adults (4.5 g/day), the primary outcome of common cold incidence was not statistically significant (p = 0.

What is the recommended dosage of ResistAid?

The clinically studied dose is 1.5 to 4.5 g/day in the immune and vaccine trials; 15 g/day in the microbiome trial. Always follow the product label and check with a healthcare provider for personal advice.

Is ResistAid safe, and does it have side effects?

For most healthy adults, ResistAid is well tolerated at studied doses. Reported effects can include: Generally extremely well-tolerated. Mild GI distress (gas, bloating) at high doses — typical of soluble fiber adjustment. It may also interact with some medications. ResistAid is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does ResistAid interact with any medications?

Possible interactions include: Generally minimal drug interactions. Immunosuppressants — theoretical concern with immune-activating ingredients; consult. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for ResistAid?

NutraSmarts rates the evidence for ResistAid as Moderate (3 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Udani JK, Singh BB, Barrett ML, Singh VJ Proprietary arabinogalactan extract increases antibody response to the pneumonia vaccine: a randomized, double-blind, placebo-controlled, pilot study in healthy volunteers. Nutrition Journal. 2010;9:32. doi: 10.1186/1475-2891-9-32.PubMedUsed to support: In a 45-person manufacturer-funded pilot trial, ResistAid increased the IgG response to the 23-valent pneumococcal vaccine for 2 of 7 tested subtypes (18C and 23F); the other five subtypes and salivary IgA were not significant. This is a surrogate antibody-titer outcome, not a reduction in infections.
  2. Udani JK Immunomodulatory effects of ResistAid: A randomized, double-blind, placebo-controlled, multidose study. Journal of the American College of Nutrition. 2013;32(5):331-8. doi: 10.1080/07315724.2013.839907.PubMedUsed to support: In a 75-person manufacturer-funded trial, ResistAid at 1.5 g/day significantly raised tetanus IgG versus placebo, but the higher 4.5 g/day dose did not, and neither dose affected influenza antibodies. This is a selective surrogate immune-marker result, not evidence of fewer illnesses.
  3. Riede L, Grube B, Gruenwald J Larch arabinogalactan effects on reducing incidence of upper respiratory infections. Current Medical Research and Opinion. 2013;29(3):251-8. doi: 10.1185/03007995.2013.765837.PubMedUsed to support: In a 199-person manufacturer-linked trial (4.5 g/day for 12 weeks), the primary outcome of common cold incidence was not statistically significant (p = 0.055); a secondary count, the number of participants who caught a cold, was significantly lower on arabinogalactan (p = 0.038) and reached significance in the per-protocol set. Symptom severity at episode onset was higher on arabinogalactan. Supportive but borderline.
  4. Chen O, Sudakaran S, Blonquist T, Mah E, Durkee S, Bellamine A Effect of arabinogalactan on the gut microbiome: A randomized, double-blind, placebo-controlled, crossover trial in healthy adults. Nutrition. 2021;90:111273. doi: 10.1016/j.nut.2021.111273.PubMedUsed to support: The only human trial of ResistAid on the gut microbiome: in 30 healthy adults taking 15 g/day for 6 weeks, the fecal Firmicutes-to-Bacteroidetes ratio fell, Bifidobacterium only tended to increase, and overall microbial diversity significantly decreased. Some minor fecal short-chain fatty acids fell. It was well tolerated.